TW202300156A - 用於治療重度憂鬱症之19-nor-c3,3-二取代c21-n-吡唑基類固醇 - Google Patents

用於治療重度憂鬱症之19-nor-c3,3-二取代c21-n-吡唑基類固醇 Download PDF

Info

Publication number
TW202300156A
TW202300156A TW111109951A TW111109951A TW202300156A TW 202300156 A TW202300156 A TW 202300156A TW 111109951 A TW111109951 A TW 111109951A TW 111109951 A TW111109951 A TW 111109951A TW 202300156 A TW202300156 A TW 202300156A
Authority
TW
Taiwan
Prior art keywords
compound
treatment
pharmaceutically acceptable
course
acceptable salt
Prior art date
Application number
TW111109951A
Other languages
English (en)
Chinese (zh)
Inventor
羅伯特 阿爾方索 雷舍
詹姆士 多赫提
杰佛瑞 馬丁 強納斯
史帝芬 傑 凱恩思
布魯斯 漢丹 剛杜斯
喬伊 麗莎 鄧巴
班邦 慎諾雅吉 愛帝維加雅
Original Assignee
美商賽吉醫療公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商賽吉醫療公司 filed Critical 美商賽吉醫療公司
Publication of TW202300156A publication Critical patent/TW202300156A/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
TW111109951A 2021-03-17 2022-03-17 用於治療重度憂鬱症之19-nor-c3,3-二取代c21-n-吡唑基類固醇 TW202300156A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202163162501P 2021-03-17 2021-03-17
US63/162,501 2021-03-17
US202163284592P 2021-11-30 2021-11-30
US63/284,592 2021-11-30

Publications (1)

Publication Number Publication Date
TW202300156A true TW202300156A (zh) 2023-01-01

Family

ID=81327141

Family Applications (1)

Application Number Title Priority Date Filing Date
TW111109951A TW202300156A (zh) 2021-03-17 2022-03-17 用於治療重度憂鬱症之19-nor-c3,3-二取代c21-n-吡唑基類固醇

Country Status (11)

Country Link
US (1) US20240245711A1 (cg-RX-API-DMAC7.html)
EP (1) EP4308162A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024510436A (cg-RX-API-DMAC7.html)
KR (1) KR20230158033A (cg-RX-API-DMAC7.html)
AU (1) AU2022238365A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023018607A2 (cg-RX-API-DMAC7.html)
CA (1) CA3213744A1 (cg-RX-API-DMAC7.html)
IL (1) IL305858A (cg-RX-API-DMAC7.html)
MX (1) MX2023010728A (cg-RX-API-DMAC7.html)
TW (1) TW202300156A (cg-RX-API-DMAC7.html)
WO (1) WO2022197901A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS62761B1 (sr) 2012-08-21 2022-01-31 Sage Therapeutics Inc Alopregnanolon za lečenje refraktornog epileptičkog statusa
SMT202100509T1 (it) 2013-04-17 2021-11-12 Sage Therapeutics Inc Steroide di c21-n-pirazolile 19-nor c3,3-disostituito per l'uso in terapia
US10246482B2 (en) 2014-06-18 2019-04-02 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
JOP20200195A1 (ar) 2014-09-08 2017-06-16 Sage Therapeutics Inc سترويدات وتركيبات نشطة عصبياً، واستخداماتها
WO2016082789A1 (en) 2014-11-27 2016-06-02 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
WO2018013613A1 (en) 2016-07-11 2018-01-18 Sage Therapeutics, Inc. C17, c20, and c21 substituted neuroactive steroids and their methods of use
TW202604538A (zh) 2016-08-23 2026-02-01 美商賽吉醫療公司 結晶19-去甲c3,3-二取代之c21-n-吡唑類固醇
US20200291059A1 (en) 2017-12-08 2020-09-17 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SMT202100509T1 (it) * 2013-04-17 2021-11-12 Sage Therapeutics Inc Steroide di c21-n-pirazolile 19-nor c3,3-disostituito per l'uso in terapia
TW202604538A (zh) * 2016-08-23 2026-02-01 美商賽吉醫療公司 結晶19-去甲c3,3-二取代之c21-n-吡唑類固醇
EP3612186A1 (en) * 2017-04-18 2020-02-26 Marinus Pharmaceuticals, Inc. Sustained release injectable neurosteroid formulations
EP3678670A1 (en) * 2017-09-07 2020-07-15 Sage Therapeutics, Inc. Neuroactive steroids and their methods of use
WO2019241442A1 (en) * 2018-06-12 2019-12-19 Sage Therapeutics, Inc. A 19-nor c3,3-disubstituted c21 -n-pyrazolyl steroid and methods of use thereof
CA3187178A1 (en) 2020-07-20 2022-01-27 Sage Therapeutics, Inc. Formulations of 19-nor c3,3- disubstituted c21-n-pyrazolyl steroid and methods of use thereof
US20230372364A1 (en) * 2020-10-01 2023-11-23 Jeremy Hill Method of treating gaba mediated disorders

Also Published As

Publication number Publication date
MX2023010728A (es) 2024-02-12
JP2024510436A (ja) 2024-03-07
US20240245711A1 (en) 2024-07-25
WO2022197901A1 (en) 2022-09-22
KR20230158033A (ko) 2023-11-17
EP4308162A1 (en) 2024-01-24
CA3213744A1 (en) 2022-09-22
IL305858A (en) 2023-11-01
BR112023018607A2 (pt) 2023-10-24
AU2022238365A1 (en) 2023-09-21

Similar Documents

Publication Publication Date Title
US20240245711A1 (en) A 19-nor c3,3-disubstituted c21-n-pyrazolyl steroid for the treatment of major depressive disorder
AU2019287491B2 (en) A 19-nor C3,3-disubstituted C21 -N-pyrazolyl steroid and methods of use thereof
AU2022267304A1 (en) Neuroactive steroid for use in treating major depressive disorder and postpartum depression in a lactating female
US20240216395A1 (en) 19-nor c3,3-disubstituted c21 -n-pyrazolyl steroid for use in treating major depressive disorder and postpartum depression
JP2024107137A (ja) 19-ノルc3,3-二置換c21-n-ピラゾリルステロイドおよびその使用方法
TW202133863A (zh) 19—nor—c3,3—二取代—c21—n—吡唑基類固醇及使用其之方法
KR20240148425A (ko) Cns-관련 장애의 치료를 위한 신경활성 스테로이드
AU2022202218A1 (en) Combination Therapy Using Acamprosate And D-Cycloserine
CN113892032A (zh) 花生口服免疫疗法中的全身过敏反应风险评估
TW202228666A (zh) 使用ghb之治療方法
AU2021343534A1 (en) TREATMENT OF NF-κB-MEDIATED DISEASE
CN117098554A (zh) 用于治疗重度抑郁障碍的19-去甲c3,3-二取代c21-n-吡唑基类固醇
JP2024544777A (ja) ハンチントン病の治療のための神経活性ステロイド
HK40109901A (en) Etrasimod for use in treating s1p1 receptor-associated disorders in combination with hormone treatment
CN117580581A (zh) 用于治疗重度抑郁障碍和产后抑郁症的19-去甲c3,3-二取代的c21-n-吡唑基类固醇
CN118765200A (zh) 用于治疗亨廷顿氏病的神经活性类固醇